Skip to content
Open in App
AbbVie logo

AbbVie

web2

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and developmen...

Symbol · 4AB
Company profile

About

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Explore by sector

Explore this sector

Presentation

Watch AbbVie

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

AbbVie completes acquisition of Apogee Therapeutics

KEY STEP

AbbVie completed its acquisition of Apogee Therapeutics for approximately $10.9 billion in equity value, adding zumilokibart and other immunology pipeline assets focused on inflammatory diseases including atopic dermatitis and asthma.

Roadmap reference
People

Company team

RA

Robert A. Michael

CEO & Chairman of the Board

Company leadership profile.

TC

Thomas Craig Freyman

Independent Director

Company leadership profile.

FH

Frederick H. Waddell

Independent Director

Company leadership profile.

BJ

Brett J. Hart

Independent Director

Company leadership profile.

MB

Melody Boone Meyer

Independent Director

Company leadership profile.

RS

Roxanne S. Austin

Lead Independent Director

Company leadership profile.

WH

William H. L. Burnside

Independent Director

Company leadership profile.

EJ

Edward Joseph Rapp

Independent Director

Company leadership profile.

RB

Rebecca B. Roberts

Independent Director

Company leadership profile.

JL

Jennifer L. Davis

Independent Director

Company leadership profile.

SE

Susan E. Quaggin

Independent Director

Company leadership profile.

TJ

Thomas J. Falk

Independent Director

Company leadership profile.

Expert coverage

2 experts evaluated AbbVie.

Orbitrum research

Experts evaluating AbbVie

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment